Physiology Cambridge Electronic Design Limited
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

News Physiol Sci 19: 154-158, 2004; doi:10.1152/nips.01462.2003
1548-9213/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matheux, F.
Right arrow Articles by Villard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matheux, F.
Right arrow Articles by Villard, J.
News in Physiological Sciences, Vol. 19, No. 3, 154-158, June 2004
© 2004 Int. Union Physiol. Sci./Am. Physiol. Soc.

Cellular and Gene Therapy for Major Histocompatibility Complex Class II Deficiency

Franck Matheux1,2 and Jean Villard1

1 Immunology and Transplant Unit, Division of Immunology and Allergology, Geneva University Hospital, 1211 Geneva 4; and
2 Department of Genetics and Microbiology, Geneva Medical School, 1211 Geneva, Switzerland
Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the Int. Union Physiol. Sci./Am. Physiol. Soc.